Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) 是胃泌素的 C-末端四肽,能刺激胃液分泌。Tetragastrin 是一种胆囊收缩素 (CCK-4) 受体激动剂。Tetragastrin 具有胃黏膜保护。
生物活性 | Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. Tetragastrin can stimulate gastric secretion[1]. Tetragastrin is a Cholecystokinin (CCK-4) receptor agonist[2]. Gastric mucosal protection[3]. |
体外研究 (In Vitro) | The antagonist of histamine H2-receptors, Cimetidine inhibits the stimulatory effect of histamine in vitro and activates Tetragastrin stimulation of the adenylate cyclase activity. Tetragastrin and histamine activate adenylate cyclase of the rat gastric mucosa via different receptors[4].
|
体内研究 (In Vivo) | In inbred Wistar rats treated with N-methyl-N'-nitro-N-nitrosoguanidine, Tetragastrin (s.c.; 1 mg/kg; every other day) treatment significantly reduces the incidence and the number of adenocarcinomas, and has a significantly lower labelling index of the antral mucosa[1]. Tetragastrin has potential for enhancing gastric mucosal protection associated with mucus secretion and/or mucus synthesis on the surface mucosa of rat gastric mucosa. A significant increase in the mucin content was noted in the mucus gel and surface mucosal layer. An increase in mucin in the mucus gel and surface mucosa would thus appear due to the administration of Tetragastrin[3].
Animal Model: | Seven-week-old male Wistar rats, each weighing approximately 160 g[3] | Dosage: | 12, 120, or 400 μg/kg | Administration: | Administered subcutaneously (s.c.); followed by 50% ethanol-induced gastric injury | Result: | Caused a significant increase in mucin content in the corpus mucosa and prevented 50% ethanol-induced gastric mucosal damage in a dose-dependent manner. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
Sequence Shortening | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Sealed storage, away from moisture Powder | -80°C | 2 years | | -20°C | 1 year |
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: DMSO : 8.33 mg/mL(13.96 mM;ultrasonic and warming and heat to 80℃) 配制储备液 1 mM | 1.6759 mL | 8.3794 mL | 16.7588 mL | 5 mM | 0.3352 mL | 1.6759 mL | 3.3518 mL | 10 mM | 0.1676 mL | 0.8379 mL | 1.6759 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (4.19 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (4.19 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (4.19 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (4.19 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (4.19 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (4.19 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|